Also known as: Forzinity
A mitochondria-targeting peptide. Approved for Barth syndrome, a rare mitochondrial disease.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Binds cardiolipin in the inner mitochondrial membrane, stabilizing energy production and reducing oxidative stress.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Longevity & energy | B | Human trials (smaller, mixed, or approved outside the US) |
| Muscle & growth hormone | B | Human trials (smaller, mixed, or approved outside the US) |
| Heart & circulation | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous daily
- Half-life
- About 4 hours
Reported dosing
40 mg SC daily (trial and label dose). Practitioner wellness use often lower.
Timing: Once daily.
Cycle: Continuous for disease; 4 to 8 week courses in wellness use.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Injection-site reactions (very common)
- Headache, dizziness
Who should avoid it
- Pregnancy
Often combined with
With MOTS-c in mitochondrial protocols.
Key findings
Accelerated FDA approval in 2025 for Barth syndrome. A larger trial in mitochondrial myopathy missed its main goal.
2026 update
Approved only for Barth syndrome; anti-aging use is unproven.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open SS-31 (Elamipretide) in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.